Association Study of SLC6A4 (5-HTTLPR) Polymorphism and Its Promoter Methylation with Rehabilitation Outcome in Patients with Subacute Stroke

Genes (Basel). 2021 Apr 16;12(4):579. doi: 10.3390/genes12040579.

Abstract

Recently it has been suggested that serotonin transporter (SLC6A4) and its 5HTTLPR polymorphism could be involved in post stroke recovery. Here, we characterized the methylation profile of two different CpG islands within the SLC6A4 promoter region in the whole blood of 50 patients with subacute stroke before and after a six-week rehabilitation treatment. These patients were genotyped for 5HTTLPR polymorphism identifying patients on the basis of short (S) and L (L) alleles: 17 patients LL, 22 patients LS and 11 patients SS. At baseline, all CpG sites for both CpG islands displayed a heterogeneous methylation percentage that were not influenced by the different genotypes. After rehabilitation, we found a significant variation in the methylation levels (increase/decrease) in the specific CpG sites of both CpG islands. The statistical analysis showed a significant relationship between the LL, LS and SS alleles and the outcome of the rehabilitation intervention (χ2 (2,50) = 6.395, p = 0.041). Specifically, we found a significant difference between patients with or without a favorable outcome in the LL (11.1% with a favorable outcome) and in the SS (54.4% with a favorable outcome) groups. Our data suggest that 5-HTTLPR polymorphisms and SLC6A4 promoter methylation may be employed as a non-invasive biological marker of recovery in patients with stroke undergoing rehabilitation.

Keywords: 5-HTTLPR polymorphism; SLC6A4; methylation; rehabilitation; stroke.

MeSH terms

  • Aged
  • Aged, 80 and over
  • CpG Islands
  • DNA Methylation*
  • Epigenesis, Genetic
  • Female
  • Genotyping Techniques
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic
  • Serotonin Plasma Membrane Transport Proteins / genetics*
  • Stroke / genetics*
  • Stroke Rehabilitation / methods*
  • Treatment Outcome

Substances

  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins